ESSA Pharma Inc (EPIX)

[catinhat]

Combo (with Pfizer's enzalutamide) patients hit PSA90 (a 90% reduction in PSA levels) within 3 MONTHS. By comparison, in enzalutamide's mono trials less than half of patients attained PSA90. Pfizer already owns 4% of EPIX.

Early combo looks terrific. And the mono is doing what they expected, they KNOW they have to adjust trial to focus on AR-driven disease, and they've done that. So going forward mono is till clearly in the game. And combo could be crazy.

No volume on the open, nobody is selling. Strong hands. I'm showing 75% Institutional and 16.65% Insider, including Pfizer with 3.8%. Per Factset.